Potential Impact of Regorafenib in Patients With HCC

Video

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).

Related Videos
Related Content